Coloplast A/S (CLPBY)
| Market Cap | 14.34B -30.5% |
| Revenue (ttm) | 4.35B +2.1% |
| Net Income | 422.22M -32.2% |
| EPS | 1.87 -32.2% |
| Shares Out | n/a |
| PE Ratio | 33.95 |
| Forward PE | 16.15 |
| Dividend | 0.22 (3.37%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | 3,848 |
| Open | 6.40 |
| Previous Close | 6.44 |
| Day's Range | 6.39 - 6.45 |
| 52-Week Range | 5.64 - 9.70 |
| Beta | 0.56 |
| Analysts | Hold |
| Price Target | 8.33 (+29.15%) |
| Earnings Date | Nov 3, 2026 |
About Coloplast
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories ... [Read more]
Financial Performance
In fiscal year 2025, Coloplast's revenue was 27.87 billion, an increase of 3.12% compared to the previous year's 27.03 billion. Earnings were 3.64 billion, a decrease of -28.03%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CLPBY stock is "Hold." The 12-month stock price target is $8.33, which is an increase of 29.15% from the latest price.
News
Coloplast expects Kerecis wound-care unit to return to growth in 2027, CFO says
Medical equipment maker Coloplast expects its Kerecis wound-care business to return to growth from January 2027 after changes to U.S. Medicare payments caused sales in outpatient settings to fall sha...
Coloplast Transcript: Q3 25/26
Q3 saw 6% organic revenue growth and 5% EBIT growth in constant currencies, with strong performance in Chronic Care and Interventional Urology, while Biologics faced headwinds from U.S. reimbursement changes. Guidance for the year remains unchanged, with continued focus on U.S. expansion, innovation, and disciplined capital allocation.
Coloplast Quarterly report: Q3 2026
Coloplast has published its Q3 2026 quarterly earnings report on August 18, 2026.
Coloplast Slides: Q3 2026
Coloplast has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 18, 2026.
Coloplast Slides: Investor presentation
Coloplast has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Coloplast's Next Generation Inflatable Penile Prosthesis Approved by the FDA – can help millions of men
The global leader within intimate healthcare today announced FDA approval of Titan Prime, an inflatable penile prosthesis (IPP) that represents the company's next-generation device and will be availab...
Coloplast Transcript: Q2 25/26
Solid H1 growth driven by core segments, but Wound & Tissue Repair and Biologics face headwinds from U.S. reimbursement changes and weak China demand. Currency and raw material inflation are expected to pressure margins, but guidance remains for 5%-6% organic growth and 5% EBIT growth.
Coloplast Quarterly report: Q2 2026
Coloplast has published its Q2 2026 quarterly earnings report on May 12, 2026.
Coloplast Slides: Q2 2026
Coloplast has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 12, 2026.
Coloplast Slides: Investor presentation
Coloplast has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26
2025/26Interim financial results, H1 2025/26 1 October 2025 - 31 March 2026 Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth1 in constant currencies. Strong quarter in Chronic Care and I...
Coloplast Receives Innovative Technology Contract from Vizient for Biatain® Silicone Fit
The contract is awarded for products that bring improvement to the healthcare industry. Coloplast, a global medical device company and market leader in intimate healthcare, has received an Innovative ...
Coloplast Transcript: Guidance
Guidance for FY 2025/2026 was revised down due to Kerecis market challenges and currency headwinds, with organic growth now expected at 5%-6%. Chronic Care and Interventional Urology remain strong, while European wound dressings face pricing pressures.
Coloplast Slides: Guidance
Coloplast has posted slides in relation to its latest quarterly earnings report, which was published on April 24, 2026.
Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis
Announcement no. 04/2026Inside information Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, reflecting a slower ma...
Coloplast A/S - H1 2025/26 Earnings Release - Invitation for conference call on 12 May 2026 at 11:00 CEST
Tuesday, 12 May 2026 at 11:00 - 12:00 CEST In connection with the publication of Coloplast's interim financial results for H1 2025/26, to be released same day around 07:30 CEST, Coloplast will host a ...
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.
Coloplast A/S - Allocation of Share Options
Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactio...
Coloplast appoints Gavin Wood as new CEO
Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief...
Coloplast A/S - Updated Financial Calendar 2025-26
Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General ...
Coloplast A/S - Interim Financial Report, Q1 2025/26
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0%...
Coloplast Transcript: Q1 25/26
Q1 delivered 6% organic revenue growth and 3% EBIT growth in constant currencies, with strong performance in Interventional Urology and ongoing challenges in Kerecis due to Medicare changes. Full-year guidance is maintained, with Kerecis' margin expected to recover and net profit to rise year-over-year.
Coloplast Quarterly report: Q1 2026
Coloplast has published its Q1 2026 quarterly earnings report on February 6, 2026.
Coloplast Slides: Q1 2026
Coloplast has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on February 6, 2026.
Coloplast Slides: Investor presentation
Coloplast has posted slides in relation to its latest quarterly earnings report, which was published on February 6, 2026.